Given that EGFRvIII and IL-13Rα2 are co-expressed in the same tumor cells, the intracellular tandem specificity between these two molecules may confer a growth advantage to the tumor, making them an ideal combination for simultaneous targeting 140. The gene discussed is IL13RA2; the disease is neoplasm.